Cytiva and Pall Life Sciences complete integration


Cytiva and the life sciences business of Pall Corporation have completed their integration and are now united as one business under the Cytiva brand.

In January 2023, the life sciences business of Pall separated from Pall Corporation. Pall’s biotech portfolio is now a product family in Cytiva’s bioprocess business. The Pall medical portfolio will remain a market brand and part of Cytiva.

Emmanuel Ligner, Danaher Group Executive, President and CEO of Cytiva, said: “The biotechnology industry is at the start of a new era. New modalities are emerging, there is greater emphasis on local manufacturing, and we are accelerating the adoption of digital solutions. Uniting Cytiva and the life sciences business of Pall gives us the focus, expertise, and talent to help our customers discover, develop, and deliver the next generation of novel therapeutics.”

The portfolio now includes brands including Allegro, Supor, iCELLis, Kleenpak, and Pegasus, in addition to ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Sefia, Whatman, Xcellerex, and Xuri.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free